Efficiency of firmagon in the patient with advanced prostate cancer after progression on standard MAB scheme: case report
https://doi.org/10.18027/2224-5057-2013-3-51-55
Abstract
Prostate cancer is the most common form of cancer in men in Western countries and in some countries is in second place in the list of leading causes of cancer death in men. About 300 000 new cases of prostate cancer registered annually in Europe. In the world this number rises to 670,000 new cases. Prostate cancer in Russia takes 4th place after lung cancer, gastric cancer and non-melanoma skin tumors. . Prostate cancer took 1st place in the list of the increase of incidence in Russia during the period 1999-2009 (by 2.8 times). Prostate tumors account for 6.9% of all malign tumors in men. Mortality due to prostate cancer is 10.4 per 100 000 in male population.
About the Authors
M. V. Kazantseva
ГБУЗ «Клинический онкологический диспансер № 1» департамента здравоохранения Краснодарского края
Russian Federation
Russian Federation
E. A. Strygina
ГБУЗ «Клинический онкологический диспансер № 1» департамента здравоохранения Краснодарского края
Russian Federation
Russian Federation
References
1. Казанцева М. В., Тесленко Л. Г, Цокур И. В., Бондарева И. С. Распространённость злокачественных новообразований в Краснодарском крае (2006—2010 годы). Краснодар, 2011, стр. 151.
2. ФГБУ Российский научный центр рентгенорадиологии Минздравсоцразвития РФ (Москва). Павлов А. Ю., Гафанов Р. А., Фастовец С. В., Герасимов А. А.,
3. Исаев Т. К. Опыт применения Фирмагона в комбинации с сочетанной лучевой терапией у больных раком предстательной железы.
4. Tombal B. et al. Lower risk of cardiovascular (CV) events and death in men receiving ADT by gonadotropin releasing hormone (GnRH) antagonist, degarelix, compared with luteinising hormone-releasing (LHRH) agonists. EAU 2013, Poster #677.
5. Miller K. et al. Lower risk of cardiovascular (CV) events and death in men receiving ADT by gonadotropin releasing hormone (GnRH) antagonist, degarelix, compared with luteinising hormone-releasing (LHRH) agonists. EAU 2013, Poster #678.
6. Klotz L et al. BJU Int 2008; 102:1531-1538.
7. Firmagon (degarelix). Summary of product characteristics. July 2012.
8. Tombal B et al. Eur Urol 2010; 57:836-42.
9. Crawford ED et al. J Urol 2011;186 (3):889-897.
10. Van Poppel H et al. Abstract (23.) Euro Urol Suppl 2007;6 (2):28.
Review
For citations:
Kazantseva M.V., Strygina E.A. Efficiency of firmagon in the patient with advanced prostate cancer after progression on standard MAB scheme: case report. Malignant tumours. 2013;(3):51-55. (In Russ.) https://doi.org/10.18027/2224-5057-2013-3-51-55
Views:
880
Email this article 